GUTS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Fractyl Investors of Securities Class Action Lawsuit Deadline on October 20, 2026

Faruqi & Faruqi, LLP is investigating potential claims against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ: GUTS) and reminds investors of the October 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you purchased or acquired securities in Fractyl between January 13, 2025 and January 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Revita was less effective than Defendants had led investors to believe, and/or operational issues at one or more of the REMAIN-1 Midpoint Cohort's clinical sites compromised the integrity of its efficacy results; (ii) accordingly, Revita's clinical, regulatory, and commercial prospects were overstated, as was the REMAIN-1 Midpoint Cohort's ability to assess Revita's efficacy; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times. On January 29, 2026, Fractyl issued a press release announcing six-month data from the REMAIN-1 Midpoint Cohort, disclosing that "Revita-treated patients experienced a 4.5% weight regain vs 7.5% in the sham arm at 6 months" and that "[t]he Midpoint Cohort was not designed to be sufficiently powered for efficacy analysis," and hosted a conference call during which CEO Rajagopalan indicated that issues at one of the study sites "had higher-than-expected regain across both arms." On this news, Fractyl's stock price fell $1.245, or 68.03%, to close at $0.585 per share on January 29, 2026. On January 30, 2026, following the release of post-market Canaccord Genuity and Morgan Stanley reports, with Morgan Stanley downgrading the Company to "Equal-weight" from "Overweight" and cutting its price target to $2.00 from $8.00, characterizing the results as "[d]isappoint[ing]." On this news, Fractyl's stock price fell $0.125, or 21.37%, to close at $0.46 per share on January 30, 2026. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Fractyl's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Fractyl class action, go to www.faruqilaw.com/[GUTS](/en/us/GUTS) or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).